
    
      This is a multi-centre, non-randomised, open label Phase I clinical trial of an Advanced
      Therapy Investigational Medicinal Product named CD19 Chimeric Antigen Receptor (CAR)
      γδT-cells (CD19 CAR γδT-cells) in patients with high risk, relapsed CD19+ haematological
      malignancies (Leukemia and lymphoma). Following informed consent and registration to the
      trial, Patients will receive the allogeneic CD19 CAR γδT-cells following lymphodepleting
      chemotherapy. The study will evaluate the safety, efficacy and duration of response of the
      CD19 CAR γδT-cells in patients with high risk relapsed CD19+ malignancies.
    
  